Acute Promyelocytic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Promyelocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-04-18Clinical Trial Update: All-trans Retinoic Acid, and Arsenic +/- Idarubicin [Phase 2]
Phase 2 trial evaluating all-trans retinoic acid with arsenic +/- idarubicin in acute promyelocytic leukemia has completed with results post…
-
CLINICAL_TRIALS trial_result · 2019-01-24Clinical Trial Update: Red Cell Transfusion Goals in Patients With Acute Leukemias [Phase 1]
Phase 1 trial completed evaluating red blood cell transfusion goals in patients with acute leukemias (acute lymphoblastic leukemia, acute my…
-
FDA approval · 2018-11-15FDA Approved: ARSENIC TRIOXIDE — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original ANDA for arsenic trioxide, marketed by Ingenus Pharmaceuticals, LLC. This approval provides generic access to arse…
-
FDA approval · 2018-11-15FDA Approved: ARSENIC TRIOXIDE — Original Application (Nexus Pharmaceuticals LLC)
FDA approved Nexus Pharmaceuticals LLC's generic arsenic trioxide under ANDA209780.
-
FDA approval · 2018-11-13FDA Approved: ARSENIC TRIOXIDE — Original Application (Nordic Pharma, Inc.)
The FDA approved the original application for a generic arsenic trioxide product from Nordic Pharma, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-11-13FDA Approved: ARSENIC TRIOXIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the original ANDA for arsenic trioxide from Zydus Pharmaceuticals USA Inc., allowing a generic version of the cancer therapy to…
-
CLINICAL_TRIALS research · 2018-09-07Clinical Trial Update: WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation [Phase 2]
Phase 2 clinical trial investigating WT1 DNA fusion gene vaccination with intramuscular injection and electroporation for haematological mal…
-
FDA approval · 2018-08-31FDA Approved: ARSENIC TRIOXIDE — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's original application for arsenic trioxide, enabling its marketing as a generic product in the United …
-
CLINICAL_TRIALS withdrawal · 2018-07-02Clinical Trial Update: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 trial of gemtuzumab ozogamicin for adults with acute myeloid leukemia, including acute promyelocytic leukemia and various cytogeneti…
-
CLINICAL_TRIALS research · 2018-04-24Clinical Trial Update: Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
A clinical trial update examining the role of microparticles in the coagulopathy of acute promyelocytic leukemia.
-
CLINICAL_TRIALS approval · 2018-03-02Clinical Trial Update: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Gemtuzumab ozogamicin has been approved for marketing for relapsed or refractory acute myeloid leukemia and acute promyelocytic leukemia bas…
-
FDA approval · 2018-01-12FDA Approved: TRISENOX — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TRISENOX (arsenic trioxide) by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2017-12-22Clinical Trial Update: S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia [Phase 2]
Phase 2 trial update examining gemtuzumab in combination with chemotherapy for previously untreated acute promyelocytic leukemia; results po…
-
CLINICAL_TRIALS trial_result · 2017-12-06Clinical Trial Update: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 trial evaluating a MEK inhibitor (MEK162) in combination with idarubicin and cytarabine for adults with relapsed or refractory acu…
-
CLINICAL_TRIALS trial_result · 2017-09-08Clinical Trial Update: Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of clofarabine, cytarabine, and G-CSF in relapsed or refractory acute myeloid leukemia…
-
CLINICAL_TRIALS trial_result · 2017-04-04Clinical Trial Update: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia [Phase 3]
Phase 3 trial update evaluating combination chemotherapy in children with newly diagnosed acute promyelocytic leukemia expressing PML-RARA; …
-
CLINICAL_TRIALS research · 2017-01-26Clinical Trial Update: Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia [Phase 3]
A Phase 3 clinical trial update for treatment in children and adolescents with acute promyelocytic leukemia; the current status is unknown.
-
CLINICAL_TRIALS trial_result · 2016-06-16Clinical Trial Update: Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
A Stanford-sponsored clinical trial evaluating allogeneic transplantation for acute and chronic leukemias has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-01-29Clinical Trial Update: Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia [Phase 2]
A Phase 2 trial evaluating tretinoin and arsenic trioxide with or without idarubicin for acute promyelocytic leukemia was terminated, and re…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
This Phase 2 trial updates romidepsin for relapsed or refractory acute myeloid leukemia, covering several AML subtypes defined by cytogeneti…
-
CLINICAL_TRIALS withdrawal · 2015-10-27Clinical Trial Update: New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia [Phase 2]
A Phase 2 trial evaluating a new retinoid agent in combination with arsenic trioxide for untreated acute promyelocytic leukemia has been wit…
-
CLINICAL_TRIALS research · 2015-10-02Clinical Trial Update: Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia
This document reports on a completed clinical trial that investigates biomarkers in tissue samples from patients with acute promyelocytic le…
-
CLINICAL_TRIALS trial_result · 2015-08-05Clinical Trial Update: Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update evaluating selumetinib in adults with recurrent or refractory acute myeloid leukemia, including AML with t(15;…
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia
A completed clinical trial update reports biomarker analyses in bone marrow samples from patients with acute promyelocytic leukemia (APL). T…
-
FDA approval · 2015-02-20FDA Approved: TRISENOX — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for Trisenox (arsenic trioxide) submitted by Cephalon, LLC.